News | July 11, 2014

DC Devices Closes $34 Million in Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure

July 11, 2014 — DC Devices Inc. has closed a $34 million Series D financing round. Accelmed led the round with contributions from existing investors Third Rock Ventures, General Catalyst Partners and Lumira Capital, as well as a new undisclosed strategic investor. Funds will be used to complete clinical evaluation of the world’s first transcatheter device for the treatment of diastolic heart failure (DHF), a $5 billion global market opportunity.

With heart failure representing the single-biggest cause of hospitalizations in many countries, and the largest expense in the U.S. Medicare budget, new therapies that reduce the heart failure hospitalization rate and improve patients’ quality of life are needed.

The company’s proprietary, minimally invasive InterAtrial Shunt Device (IASD) system is the world’s first device intended to treat DHF, also known as heart failure with preserved ejection fraction (HFpEF). By placing a permanent implant in the atrial septum, the IASD System is designed to reduce elevated left atrial pressure and relieve symptoms. The innovative IASD System allows physicians to perform this transcatheter treatment without open-heart surgery and in a controlled fashion, using standard interventional cardiology techniques.

“Patients who suffer from diastolic heart failure have no effective treatment options and have a poor survival rate,” said George Fazio, president and CEO of DC Devices. “With the support of our investors and the guidance of our clinical advisors, we are now one step closer to bringing a potentially transformative new therapy to heart failure patients around the world.”

The DC Devices clinical advisory board is comprised of a group of international, multi-specialty, leading physicians who bring a broad range and depth of expertise to the company. The advisory board, which provides medical and strategic guidance for product development, clinical, and commercialization activities, includes Drs. Martin Leon, Gerd Hasenfu?, Sanjiv Shah, David Kaye, Piotr Ponikowski, Daniel Burkhoff, Ted Feldman, Laura Mauri, Matthew Maurer, John Cleland and Barry Borlaug among others.

For more information: www.dcdevicesinc.com

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Overlay Init